nano-composite screening
Diagnostic TestRecovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses
NCT Number: NCT04380194
Objective: To demonstrate the presence of bioresistant intracorporeal carbon-based nanocomposites in subjects exposed to a fulguration, in the immediate aftermath of this fulguration and 24 months (+/- 6 months) after the accident, on blood and urine samples, then in comparison with blood and urine samples from 14 healthy subjects.
Hypothesis: Lightning discharge in the human body reveals the presence of multi-functional nanoparticles which are reassembled under the impact of the electric discharge into nanostructured films, filaments and aggregates; they consist of dispersed graphene-like nanoparticles embedded in an aliphatic cross-reticulated matrix. The high electrical conductivity of the nanoinclusions, their refractory properties and the cross-reticulation of the nanoassemblages explain their biorésistance.
The graphene-like multi-functional nanoparticles are assumed to trace a population of aerosols formed in the atmosphere by plasma discharge which is present in air, water and all natural resources. Their ability to undergo changes from folded nanosheets to confined ultra-fine nanoparticles allow them to be inhaled or absorbed by the human body, or to be ingested with food.
Looking for future studies?
Notify Me7 year–80 year
All sexes
Observational
CH Henri Mondor, Aurillac, France
In order to detect nanocomposites in patients who have been impacted by lightning, an analysis protocol will be performed on the remains of blood and urine samples from their initial medical admission. After filtering the blood and urine samples, the remaining nanocomposites are selected for characterization, at micro to nanoscale, using the scanning electron microscope and the transmission electron microscope.
Based on laboratory experiments, a second sampling of blood and urine will be performed 24 months (+/-6 months) after the lightning strike to follow the delayed production of nanocomposites from the remaining activated nanoparticles.
In order to describe the neurological disorders of the patients, initial clinical, biological and radiological data will be collected in the patients' medical records and a new clinical examination will be performed at 24 months (+/- 6 months) after fulguration.
-Search for descriptive data.
Data collected:
Data collected :
Data collected :
Data collected :
H0 will be the time when the accident took place. H0-H12: Collection of clinical, biological and radiological information in the patient's medical record. Recovery at M24 (+/- 6 months) for immediate or prolonged initial neurological disorders.
At M24 (+/- 6 months): medical examination at the patient's home to :
At M24 (+/- 6 months): Description of the evolution of neurological disorders in time, recovery quality and location.
Description of measures taken to reduce and avoid bias
Measurement bias:
Selection bias:
Memory bias:
Sampling bias:
In order to better understand the mechanisms of in vivo formation of these nanocomposites, an attempt will be made to identify them in healthy subjects.
-Qualitative and quantitative aspects of bioremediation nanocomposites possibly identified in the blood of subjects not affected by lightning-strike.
Analysis of the blood of 14 healthy patients for:
Low levels of bioresistant nanocomposites are expected in this group. The aim is to trace the occurrence of nanocomposites formed by plasma discharges in the atmosphere which have passed through the alveolar and digestive barrier into the bloodstream.
The blood of healthy subjects will be collected at the Aurillac CH laboratory by taking an additional 18 ml on sodium heparinate tube during a blood test for routine check-up (INR monitoring for example). Patients will be given an information note and a consent form stating that they accept this additional volume of sample. They will inform their work and their commune of residence.
The samples will be anonymised and packaged for transport to the Aurillac laboratory for analysis under a stereomicroscope microscope in the alcoholic liquid phase. They will then be sent in dry form to the CNRS for analysis by scanning and transmission electron microscope.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-Patients exposed: all subjects who were victims of the fulguration accident.
Non-exposed patients:
Exclusion criteria
Recovery of the bottoms of the victims' blood and urine tubes at H+4. Blood and urine samples from the victims at two years of age. Single blood and urine samples from the witnesses
Time frame: Day 0
Characterization in blood
Time frame: Month 24
Characterization in blood
Time frame: Hour 12
Characterization in urine
Time frame: Month 24
Characterization in urine
Time frame: Day 0
Research and description of neurological disorders with questioning of date of onset and duration
Time frame: Month 24
Research and description of neurological disorders with questioning of date of onset and duration
Time frame: Day 0
Research and description of neuropsychological disorders with questioning of date of onset and duration
Time frame: Month 24
Research and description of neuropsychological disorders with questioning of date of onset and duration
University Hospital, Clermont-Ferrand
Other
Detection of Intracorporeal Bioresistant Nanocomposites Tracing Short- and Long-term Neurological Disorders in a Collective Fulguration
Acronym: Fulgurnano
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06750692
Brain Diseases, Cardiovascular Diseases
Afyonkarahisar, Turkey (Türkiye)
View Trial DetailsNCT06485830
Brain Damage, Chronic, Brain Diseases
Córdoba, Cordoba, Spain
View Trial DetailsNCT06270095
Nervous System Diseases, Neurologic Disorder
Roissy CDG, France
View Trial DetailsNCT06932978
Nervous System Diseases, Neurologic Disorder
Edinburgh, United Kingdom
View Trial Details